10-Q: GE HealthCare Reports Strong Q2 Earnings Amid Strategic Acquisitions and Share Buyback

GE HealthCare Technologies Inc. reported increased revenues, net income, and earnings per share for the second quarter and first half of 2025, driven by service growth and strategic acquisitions, despite macroeconomic headwinds and tariff impacts.

Summary

• Total revenues for the three months ended June 30, 2025, increased 3% to $5,007 million, with organic revenue growth of 2%.
• Total revenues for the six months ended June 30, 2025, increased 3% to $9,784 million, with organic revenue growth of 3%.
• Sales of services grew 7% to $1,743 million for the three months and 5% to $3,404 million for the six months, primarily from new and existing customer contractual agreements.
• Net income attributable to GE HealthCare increased 13% to $486 million for the three months and 31% to $1,049 million for the six months.
• Diluted earnings per share (EPS) rose to $1.06 for the three months (from $0.93) and $2.29 for the six months (from $1.75).
• Operating income increased 8% to $654 million for the three months and 12% to $1,283 million for the six months.
• Adjusted EBIT decreased 2% to $729 million for the three months but increased 1% to $1,443 million for the six months.
• Free cash flow for the six months ended June 30, 2025, was $106 million, up 15% from $92 million in the prior year.
• Acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (NMP) for $271 million net cash, recognizing a $97 million gain on remeasurement of the existing interest.
• Board authorized a $1,000 million share repurchase program on April 30, 2025, with $100 million repurchased during Q2 2025.
• Issued $1,500 million in new senior unsecured notes in Q2 2025 and repaid $250 million of the Term Loan Facility.

Sentiment

Score: 7

Explanation: The company demonstrated strong growth in net income, EPS, and free cash flow, indicating solid financial performance. Strategic acquisitions like NMP contributed positively, and the resolution of FCPA investigations removes a significant overhang. However, the decline in Adjusted EBIT for the quarter, ongoing impacts from tariffs, and delays in the crucial China market present notable headwinds and cost pressures, preventing a higher score.

Positives

• Strong growth in Net Income attributable to GE HealthCare, up 13% to $486 million for Q2 2025 and 31% to $1,049 million for H1 2025.
• Diluted EPS increased significantly to $1.06 for Q2 2025 (from $0.93) and $2.29 for H1 2025 (from $1.75).
• Total revenues grew 3% reported and 2% organically for Q2 2025, and 3% reported and 3% organically for H1 2025.
• Sales of services showed robust growth, increasing 7% for Q2 2025 and 5% for H1 2025, driven by new and existing customer contractual agreements.
• Free cash flow increased 15% to $106 million for H1 2025.
• Successful acquisition of the remaining 50% interest in Nihon Medi-Physics (NMP), which contributed to PDx segment revenue growth and resulted in a $97 million remeasurement gain.
• Board authorized a $1,000 million share repurchase program, demonstrating commitment to shareholder returns, with $100 million already repurchased in Q2 2025.
• Received letters from the SEC and DOJ closing investigations related to Foreign Corrupt Practices Act (FCPA) without further action, resolving a significant legal uncertainty.
• PDx segment revenues grew 14% reported and 5% organically for Q2 2025, and 10% reported and 6% organically for H1 2025, indicating strong performance in pharmaceutical diagnostics.
• USCAN revenues grew 4% for Q2 2025 and 6% for H1 2025, showing strong performance in key regions.

Negatives

• Gross profit decreased by $17 million for Q2 2025 and decreased 170 basis points as a percent of Total revenues, primarily due to an increase in both Cost of products sold and Cost of services sold.
• Cost of products sold increased 240 basis points as a percent of sales for Q2 2025, driven by cost inflation and incremental tariffs.
• Cost of services sold increased 90 basis points as a percent of sales for Q2 2025, due to unfavorable mix and cost inflation, including incremental tariffs.
• Adjusted EBIT decreased 2% for Q2 2025, primarily due to the decrease in Gross profit.
• Imaging Segment EBIT decreased by $20 million for Q2 2025 due to cost inflation, including the impacts of incremental tariffs.
• PCS Segment EBIT decreased by $18 million for Q2 2025 and $51 million for H1 2025, primarily due to cost inflation and unfavorable mix.
• China region revenues decreased 3% for Q2 2025 and 2% for H1 2025, impacted by delays in the government's 2024 stimulus program.
• Non-operating benefit income decreased $28 million for Q2 2025 and $56 million for H1 2025, primarily due to lower expected returns on plan assets.

Risks

• Operating in highly competitive markets.
• Global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflicts and tensions (e.g., Ukraine and Russia, Middle East).
• Public health crises, epidemics, and pandemics, and their effects on the business.
• Changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers.
• Demand for products, services, or solutions and factors that affect that demand.
• Developments in the market in China, including slower-than-anticipated implementation of the 2024 stimulus program.
• Ability to control increases in healthcare costs and any subsequent effect on demand for products, services, or solutions.
• Ability to successfully complete strategic transactions.
• Impacts related to increasing focus on and investment in cloud, edge computing, artificial intelligence (AI), and software offerings.
• Management of supply chain and ability to cost-effectively secure the materials needed to operate the business.
• Disruptions in operations.
• Actions or inactions of third parties with whom the company partners and the various collaboration, licensing, and other partnerships and alliances.
• Impact of potential information technology, cybersecurity, or data security breaches.
• Maintenance and protection of intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies.
• Ability to attract and/or retain key personnel and qualified employees.
• Environmental, social, and governance matters.
• Compliance with the various legal, regulatory, tax, privacy, and other laws to which the company is subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions.
• Impact of potential product liability claims.
• Level of indebtedness, as well as the general ability to comply with covenants under debt instruments, and any related effect on the business.
• Tariffs materially impacted profitability and cash flows for the three months ended June 30, 2025, and are expected to continue to have a material impact, with the company not expecting to fully offset additional costs.
• The potential inability to repatriate earnings from Russia and Ukraine, although not expected to have a material impact on the ability to operate.
• No guarantee of obtaining all applied-for licenses for supplying customers in Russia on a timely basis, or that business in Russia will not be further disrupted.
• Geopolitical instability, including the recent conflict between Israel and Iran and other disruptions in the Middle East, could adversely impact operations, supply chains, and logistics, potentially resulting in increased costs and delays.

Future Outlook

The company expects the 2024 stimulus program in China to create longer-term opportunities, but short-term delays in orders and revenues are anticipated to continue. Approximately $350 million in total cash contributions to postretirement benefit plans are expected in 2025. The One Big Beautiful Bill Act (OBBBA) is not expected to have a material impact on income taxes, though a full evaluation is ongoing. The company plans to use net proceeds from the recent debt issuance, along with cash on hand, to repay the $1,500 million senior unsecured notes due in November 2025. Substantially all product-related remaining performance obligations are expected to be recognized within two years, and services-related within five years. Additional restructuring expenses of approximately $34 million are expected, primarily over the next 12 months.

Management Comments

• We believe that our existing balance of Cash, cash equivalents, and restricted cash, future cash generated from operating activities, access to capital markets, and existing credit facilities will be sufficient to meet the needs of our current and ongoing operations, pay taxes due, service our existing debt, and fund investments in our business for at least the next 12 months.
• We continue to monitor developments in the market in China. In March 2024, the government in China announced a new stimulus program (2024 stimulus) that includes the healthcare sector and is being implemented through Chinas provinces. We expect the 2024 stimulus program will result in opportunities for our business in China in the longer term, but it has had short-term impacts as provinces develop and announce their plans and customers begin to make purchasing decisions, which has progressed slower than originally anticipated. We expect these delays to continue to impact our orders and revenues in the near term, although we are unable to predict the exact duration or magnitude of the impact.
• While we are taking actions to mitigate the impact of tariffs, we do not expect to be able to fully offset the additional costs or other negative impacts resulting from the tariffs.

Industry Context

The company operates in the highly competitive global healthcare solutions market, providing medical technology, pharmaceutical diagnostics, and integrated AI-enabled solutions. Its performance is influenced by global macroeconomic conditions, trade policies (tariffs), government spending and reimbursement changes, and geopolitical stability. The company is increasing its focus and investment in cloud, edge computing, and AI software offerings, aligning with broader industry trends towards digital transformation in healthcare. Developments in the China market, including government stimulus programs, are a significant factor for future growth.

Corporate Governance

Legal Proceedings

• Contracts with Iraqi Ministry of Health: A complaint alleging violations of the U.S. Anti-Terrorism Act by providing funding to an Iraqi terrorist organization through sales practices. The Supreme Court vacated the D.C. Circuit's decision on June 24, 2024, and remanded the case for further consideration. The D.C. Circuit heard oral argument on November 19, 2024, with a decision pending. Proceedings in the District Court are currently inactive.
• Government Disclosures (FCPA/China): Voluntary self-disclosures made to the SEC and DOJ regarding tender irregularities and potential FCPA violations in certain Chinese provinces. Both the SEC (May 16, 2025) and DOJ (May 28, 2025) closed their respective investigations without further action.

Related Party Transactions

• General Electric Company (now GE Aerospace) continues to be considered a related party due to the nature of the relationship and board member affiliation following the Spin-Off on January 3, 2023.
• Net costs incurred with GE were not significant for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, and the authorization of a $1,000 million share repurchase program. A cash dividend of $0.035 per share was declared.
• Employees: Restructuring activities involve workforce reductions, leading to employee termination costs.
• Customers: Delays in purchasing decisions in the China market due to the slower-than-anticipated implementation of the government's stimulus program.
• Suppliers: Participation in voluntary supply chain finance programs allows suppliers to sell receivables to third parties.
• Creditors: The company issued $1,500 million in new senior unsecured notes and repaid $250 million of its Term Loan Facility, demonstrating active debt management. The company remains in compliance with debt covenants.

Next Steps

• Repay $1,500 million aggregate principal amount of senior unsecured notes due November 2025 using proceeds from newly issued debt and cash on hand.
• Continue evaluating the full impact of the One Big Beautiful Bill Act (OBBBA) on the business.
• Continue to monitor global markets for changes in customer behavior, government spending, reimbursement, and indirect impacts from tariffs.
• Continue to apply for licenses to supply customers and support business in Russia, as required.
• Continue to assess developments related to the Russia-Ukraine conflict and Middle East conflicts for material impact.
• Incur additional restructuring expenses of approximately $34 million, primarily over the next 12 months.

Key Dates

Recommendation

While GE HealthCare demonstrated strong growth in net income, EPS, and free cash flow, indicating operational efficiency and financial health, there are notable headwinds. The decline in Adjusted EBIT for the quarter, persistent cost inflation, and the material impact of tariffs on profitability are concerns. Furthermore, the slower-than-anticipated progress of the China stimulus program is causing near-term delays in orders and revenues in a key market. The positive resolution of the FCPA investigations and the share repurchase program are favorable, but the ongoing challenges suggest a 'hold' recommendation until there is clearer evidence of sustained Adjusted EBIT growth and mitigation of macroeconomic and trade-related pressures.

Keywords

Healthcare Technology, Medical Devices, Pharmaceutical Diagnostics, Medical Imaging, Patient Care Solutions, Radiopharmaceuticals, Artificial Intelligence in Healthcare, SEC Filing, Quarterly Report, Financial Results, Earnings, Revenue, Profitability, Cash Flow, Acquisitions, Share Repurchase, Global Trade, Tariffs, China Market, Supply Chain, Corporate Governance